Atlas Trials

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Clinical trial NCT06803875 · RECRUITING

Trial details

NCT number
NCT06803875
Sponsor
Roberto Chiarle
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-risk Neuroblastoma
Start date
2025-01-31
Primary completion
2027-12-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.